Bioton Acquires BioPartners For $78M In Stock, Debt

Polish biotechnology firm Bioton SA continued its expansion into Western Europe by picking up Swiss biosimilar drug developer BioPartners Holdings AG in a stock-based deal valued at $77.8 million. That total includes $15.8 million in BioPartners debt, as well as 81.5 million Bioton shares, valued at around PLN183.4 million (US$62 million). (BioWorld International)